- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
USFDA Issues No Action Indicated Classification to Cipla's InvaGen Facility in New York

Mumbai: Cipla Limited has announced that the United States Food and Drug Administration (USFDA) has classified the inspection conducted at its wholly owned subsidiary InvaGen Pharmaceuticals Inc.'s manufacturing facility in Hauppauge, Long Island, New York, USA, as No Action Indicated (NAI).
In a regulatory filing, Cipla informed the stock exchanges that it had received communication from the USFDA regarding the outcome of the inspection conducted at the InvaGen manufacturing facility between October 19 and October 22, 2026.
The inspection was previously disclosed by the company through an intimation dated October 23, 2026. Following the inspection, the USFDA communicated its classification on November 17, 2026, assigning the facility a No Action Indicated (NAI) status.
The NAI classification indicates that the USFDA did not identify any conditions warranting regulatory or enforcement action based on the inspection findings.
InvaGen Pharmaceuticals Inc. is a wholly owned subsidiary of Cipla Limited, a Mumbai-headquartered pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical products across various therapeutic categories.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

